Q3 2025 Trading Update

AI SummaryClose X

Shield Therapeutics PLC reported its Q3 2025 trading update, highlighting its strongest quarterly performance to date. ACCRUFeR® prescriptions grew by approximately 15% compared to Q2 2025, reaching roughly 54,000. This prescription volume drove net revenues to $13.1 million, with an average net selling price of $237. In comparison, Q3 2024 saw $7.2 million in net revenues from approximately 44,000 prescriptions at an average net selling price of $167. The company's cash and cash equivalents stood at $8.6 million as of September 30, 2025. Shield Therapeutics remains on track to achieve cash flow positivity by the end of 2025.

Disclaimer*

UK 100

Latest directors dealings